Relative Weight of the Variables Evaluated Through the Therapeutic Positioning Reports in the Pricing and Reimbursement of Oncological and Oncohematology Medicines in Spain

The white paper available only in Spanish language

By Bordoy Coma-Cros Clara, Cruz Arrioja Jessica, Manau Vilalta Marc, Castillo Gutiérrez Chus, Vázquez Roso Manuel

Pricing & reimbursement (P&R) decisions for new drugs in Spain are based on the criteria set in the Law on Guarantees and Rational Use of Medicinal Products (LGURM) (RD 1/2015), and the clinical evidence, economic value, and positioning of each new drug in relation to the Therapeutic Positioning Report (TPR). Despite this clear framework, the weight of each criterion on P&R decisions is not transparent.

For oncology therapies in particular, timeline of the P&R decision is critical, however, the gap between the approval of new medicines by EMA and their reimbursement in Spain can be noticeable. As of January 2022, more than 100 TPRs had a delay of 400 days. Both clinicians and patients regret these delays in access and want to streamline evaluation processes with new TPRs.

This white paper explores how companies’ target prices are impacted by the different variables leveraged during the P&R process for oncology and oncohematology’s first indication.

White Paper Summary: Methodology, results, and recommendations

Based on LGURM and TPRs, hypotheses around the relationship between different variables and expected price were developed. Then, using the Wilcoxon or Kruskal-Wallis tests, those hypotheses were statistically analyzed.

Although the process is complex and heterogeneous, the additional clinical benefit is a statistically significant criterion in the decision-making process. While there is no statistically significant relationship between other factors when predicting P&R results, there are interesting trends.

A more structured, transparent, and predictable methodology that considers LGURM priorities would help set expectations and communication among stakeholders. Despite the limited sample, the results can serve as a starting point to increase transparency and improve process structure to encourage a more fluid dialogue in evaluating and financing drugs in Spain.

Have questions or comments about the white paper “Relative Weight of the Variables Evaluated Through the Therapeutic Positioning Reports in the Pricing and Reimbursement of Oncological and Oncohematology Medicines in Spain”? Contact us.

Publications
Published on:
October 5, 2022
Written by:
Bordoy Coma-Cros Clara, Cruz Arrioja Jessica, Manau Vilalta Marc, Castillo Gutiérrez Chus, Vázquez Roso Manuel

Related news

News November 15, 2022
Alira Health Partners with Policy Matters to Foster Market Access in the UK
Alira Health, a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, announces its partnership with leading UK market access specialist(...)
Digital Health Healthcare Consulting Market Access
News November 10, 2022
Alira Health and GDMH together to boost Life Sciences innovation
The companies join forces for collaborative research and co-development of projects in the fields of Digital Health, Real-World Evidence and Market Access.
Clinical Trials Digital Health DTx Market Access Real-World Evidence RWE
Publications November 8, 2022
Debate sobre los IPT en oncología: buscando puntos de mejora en la evaluación y acceso de los fármacos oncológicos en España
For our Spanish community members, we are glad to share the Debate on IPT in oncology: Looking for points of improvement in the evaluation and access of oncological drugs in Spain.
Oncology Pharma Spain
Events October 7, 2022
Debate Sobre los IPT en Oncología
We are pleased to announce our next event, “Debate Sobre los IPT en Oncología,” focusing on price and reimbursement (P&R) of vital oncology and oncohematology therapies.
Market Access Product Development Regulatory
Publications October 5, 2022
Relative Weight of the Variables Evaluated Through the Therapeutic Positioning Reports in the Pricing and Reimbursement of Oncological and Oncohematology Medicines in Spain
Discover how companies’ target prices are impacted by the different variables leveraged during the P&R process for oncology and oncohematology’s first indication.
Market Access Oncology Spain
News October 4, 2022
Alira Health enhances its market access services through a strategic partnership with Centivis
Alira Health, a global healthcare advisory and technology company, announced a strategic partnership with Centivis AG, a boutique market access consulting agency, specializing in digital(...)
Digital Health Market Access MedTech Pharma Regulatory
News September 27, 2022
AseBio and Alira Health Partner to Foster Market Access for Biotech Startups
Alira Health and AseBio, the Spanish Bioindustry Association, are joining forces to support Spanish biotech companies looking to enter new markets.
Biotech Market Access Startups
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.